K4 Elite logo K4 Elite
Home / Peptide Library / Adalank
Emerging Research

Adalank

Cognitive & Neurological · ['Adalank', 'N-Acetyl Selank Amidate', 'Acetylated Selank analog']

Adalank is a synthetic derivative of the peptide Selank (a tuftsin-derived heptapeptide) described in secondary sources as an N-terminally acetylated, C-terminally amidated analog intended to improve stability. It is offered strictly for laboratory research and is studied in the context of GABAergic and BDNF-related signaling.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Emerging Research
Browse the store →
🧬

Adalank is a research peptide described as a modified form of Selank, which is itself a synthetic analog of the immunomodulatory tetrapeptide tuftsin. Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Adalank is characterized in supplier and secondary literature as bearing N-terminal acetylation and C-terminal amidation intended to increase stability and blood-brain-barrier permeability relative to the parent peptide.

As a proprietary analog, Adalank does not have a verified PubChem entry and its precise structure is reported inconsistently. The scientific rationale is largely extrapolated from the more extensively published work on Selank.

All content here is compiled from published literature on Selank and from secondary descriptions of the analog. Adalank is intended for research use only and is not a drug, supplement, or medical product.

Selank-family peptides are studied for reported anxiolytic-like and immunomodulatory activity. Published research describes effects on GABAergic neurotransmission-related gene expression and on brain BDNF, as well as modulation of enkephalin-degrading enzyme activity, in animal models.

The acetylation and amidation modifications attributed to Adalank are, on chemical grounds, expected to slow enzymatic degradation. Direct mechanistic data specific to Adalank itself is limited in the peer-reviewed literature.

  • GABAergic gene expression: Selank has been reported to affect expression of genes involved in GABAergic neurotransmission in rodent brain (Kolik et al. / Volkova et al., 2016).
  • Anxiolytic-like behavior: Selank has been studied in animal anxiety models and in a clinical trial context for generalized anxiety in Russian literature.
  • BDNF and neuroplasticity: Research reports effects of Selank on hippocampal BDNF expression in rodents.
  • Enkephalinase modulation: Selank has been reported to inhibit degradation of enkephalins, influencing the endogenous opioid system in animal models.
  • Peptide stabilization chemistry: N-terminal acetylation and C-terminal amidation are established strategies studied for improving peptide half-life.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Reporting only — not guidance. Volkova et al. (2016, Front Pharmacol / related work) administered Selank to rodents and used gene-expression profiling to describe changes in GABAergic neurotransmission-related transcripts. This describes a published animal study of the parent peptide.

Zozulya et al. (2008, Bull Exp Biol Med) reported a clinical evaluation of Selank versus a benzodiazepine comparator in generalized anxiety, describing anxiolytic-related outcomes. These summaries describe existing published studies of Selank and are not recommendations or protocols for use of Adalank.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

SelankNeutral
Structurally related parent peptide; comparative research context only.
Adamax / Semax analogsCompatible
Appear together in cognitive-research literature; no established combined-use data.
GABAergic agentsCaution
Mechanistic overlap on GABA signaling in animal models; no controlled interaction data.
Enkephalin/opioid pathway agentsCaution
Selank reportedly modulates enkephalinase; combined effects uncharacterized.
  1. Volkova A et al. Selank Administration Affects Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol 2016 (PMC4757669)
  2. Zozulya AA et al. Efficacy and safety of Selank in anxiety disorders. Bull Exp Biol Med 2008
  3. Kozlovskii II, Danchev ND. The effect of the synthetic peptide Selank on behavior. Neurosci Behav Physiol
Is Adalank approved for human use?
No. Adalank is a research compound with no regulatory approval. It is intended for laboratory research use only and is not a drug, supplement, or medical product.
How does Adalank relate to Selank?
Adalank is described as an acetylated, amidated analog of Selank intended to improve stability. Most published mechanistic and clinical data pertains to the parent peptide Selank.
Does Adalank have a PubChem entry?
No verified PubChem CID was found for Adalank as a distinct compound, so no molecular identifiers are listed. We do not publish fabricated identifiers.
What has been studied about this compound?
Published research on Selank reports effects on GABAergic gene expression, BDNF, and anxiolytic-like behavior in animals, plus limited clinical data. Data specific to the Adalank analog itself is limited.
Can you provide dosing information?
No. This reference provides research context only and does not include human or veterinary dosing, routes, or administration guidance.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.